RPRX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 2.49%, SMA50 9.41%, SMA200 20.66%). The stock’s 14-day RSI is 71.97 (overbought), while the ATR of 0.83 points to moderate volatility. The stock remains hovering near 52-week lows, trading -1.69% below its high and over 52.93% above its low. Average 10-day trading volume of 3.87 million shares is slightly above the 3-month average of 3.48 million, indicating heightened recent market interest.

Royalty Pharma plc generated EPS of $1.78 over the past year. Five-year average earnings growth is -7.26%. Wall Street analysts project EPS growth of 7.4% annually over the next five years. The latest quarter delivered EPS of $0.52. The next quarter is forecast at $1.07. Next year's EPS is expected at -$6.32. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $54.00 to $42.00. The high target offers 19.05% upside. The low target suggests -7.41% downside. The mean target is $47.83. This offers 5.45% upside. Royalty Pharma plc earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -53.6%. The prior quarter beat by 10.68%. Over the last six quarters, Apple has recorded several small beats. These include -82.01% in August 08, 2024.

Royalty Pharma plc has 432.29 million shares outstanding. The public float is 379.85 million shares, elevated short interest at 3.57% of float. This equals 15.18 million shares. The short ratio is 5.25 days. Institutional investors hold 90.33% of the float. Insiders own 8.73%. GG 1978 SICAF SIF S.A. holds 22.08 million shares, GG 1978 SICAF SIF S.A. - GG Strategic has 21.43 million shares and Giuliani Mario Germano has 7.80 million shares. Over the past six months, insider transactions show net selling. They sold 451.67 thousand shares across 25 transactions.

Royalty Pharma plc last paid a dividend of 0.9 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $120.07. This means the shares are trading below this model’s fair value.

Royalty Pharma plc (NASDAQ:RPRX) closed at $45.36 USD, losing -$0.17 (-0.37%) from the previous close of $45.53. The stock is currently mid-range between its 52-week high and low $29.66 and $47.86. With a market capitalization of about $19.43 billion, Royalty Pharma plc is classified as a large-cap and shows lower-than-market volatility (beta ~0.42). Key stats such as the average daily volume over the past year has been around 3.61 million shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Royalty Pharma plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pablo Legorreta, the company employs approximately 75 people and listed since June 16, 2020. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.

Royalty Pharma plc trades at a P/E ratio of 25.41, slightly below the S&P 500 average, with a price-to-sales ratio of 8.17 and a price-to-book ratio of 3.02 trading at moderately above to book value. The P/FCF stands at 7.81, also below market averages.

Our AI price prediction model suggests that Royalty Pharma plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.6%, with price expected at $45.09 by April 03, 2026, within a range of $44.35 to $45.84 3-Month Outlook: Projected rise of 41.78%, reaching $64.31 by June 18, 2026, with a range of $62.43 to $66.97. 1-Year Outlook: Projected gain of 8.2%, with price at $49.08 by March 19, 2027, within a range of $47.13 to $50.57.

Royalty Pharma plc (NASDAQ:RPRX) shares are flat 1.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Royalty Pharma plc trading at a premium to the broader market with a P/E of 25.41. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $50.82, suggesting 12.04% upside. Our AI forecast model points to short-term weakness (-0.6% over two weeks), a medium-term rise (41.78% over three months), and a longer-term gain (8.2% over one year), with expected trading ranges indicating moderate volatility.